Therapeutic Innovations for Monkeypox Inhibition
This review investigates biomaterial-based strategies for improved treatment of MPXV. We focus on emerging synthetic biomedical approaches to combating the virus. These include peptide nucleic acids, CRISPR-based systems, and small-molecule therapeutics. These methods work by targeting and blocking viral proteins and enzymes. Such synthetic platforms may help reduce viral transmission and minimize side effects. They also offer potential solutions to challenges such as viral resistance in humans. In addition, biomaterials contribute to the development of more stable and effective vaccines. Combining these biomaterials with mRNA technology provides a promising framework for future vaccine development. Overall, this review underscores biomaterial-driven antiviral systems as a major frontier in translational medicine with profound implications for global health and pandemic awareness.
Authors
- Kamala Mitra (ORCID: https://orcid.org/0000-0002-3507-5999)
- Debmalya Bhunia (ORCID: https://orcid.org/0000-0001-8649-0466)
- Nayan De (ORCID: https://orcid.org/0000-0002-0536-9849)
- Md Sorique Aziz Momin (ORCID: https://orcid.org/0000-0003-0980-8623)
- Jhuma Bhadra (ORCID: https://orcid.org/0000-0002-3892-7333)
- Achinta Sannigrahi
Institutions
- Mahindra Group (India) (IN)
- Rochester Institute of Technology (US)
- Indian Association for the Cultivation of Science (IN)
- Cold Spring Harbor Laboratory (US)
- University of Arkansas at Fayetteville (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- International Journal of Molecular Sciences
- Published
- 2026-05-12
- DOI
- https://doi.org/10.3390/ijms27104307
- Primary Topic
- Poxvirus research and outbreaks
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Science and Engineering Research Board